Best Countries For Oncology Clinical Research
Chicago, IL – KMR Group recently completed their Best Places For Clinical Research report series for 2016. The Best Places series continues to highlight the strengths and weaknesses of nearly 100 countries for over a dozen different therapy areas and diseases. This year’s analyses confirm existing Industry trends while highlighting some surprising new shifts.
The Best Places For Clinical Research reports ranks countries for specific disease areas using eight KPIs that assess performance, infrastructure, patient access, as well as cost. The results are presented for each individual metric in addition to an aggregate score which combines all of them together to come up with a singular overall rank.
This year the Oncology focused report highlights the strength of Eastern Europe, which now ranks second regionally right below Asia (excluding Japan). North America and Western Europe rank third and fourth respectively, while the Middle East and Africa perform the worst with the lowest regional scores.
China remains the top country overall, but Russia, Ukraine, Poland, and Romania rank close behind. All these countries have relatively strong infrastructures for Oncology, but really outperformed other countries with their strong recruitment rates and access to patients. This highlights the importance emerging markets have had for the Industry over the last several years in maintaining and improving clinical development performance. The United States, which now ranks seventh globally, has the strongest infrastructure and patient volume across countries, but has high costs and only average recruitment performance which hinders its ranking.
“Understanding the shortcomings of certain countries within diseases as well as identifying the strongest performers is critical in trial planning and management. These reports serve as a strong foundation that can play a critical role in the early stage planning process and set reliable benchmarks in trial plans,” comments Linda Martin, President and Founder of KMR Group.
About KMR
KMR Group has worked exclusively in biopharmaceutical R&D since the early 1990s. KMR Group is an industry leader in benchmarking, analytics and performance management as well as a developer of on-line analytics tools that enable access to their propriety and rich datasets. KMR's clinical platform contains the most reliable source for trial performance, recruitment and site metrics data, with over 25,000 global clinical trials. Clients rely on these tools to benchmark performance, define recruitment strategies and shape enrollment plans and to identify best performing sites. For more information or for a demonstration of any of KMR's tools, please contact us. Visit our website at https://kmrgroup.com Follow us on Twitter @KMRGroupInc
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
